Preferred Label : FLT3 Inhibitor BMF-500;
NCIt definition : An orally bioavailable, covalent and selective inhibitor of FMS-like tyrosine kinase
3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration,
FLT3 inhibitor BMF-500 selectively targets and irreversibly binds to a reactive cysteine
in the active site of FLT3. This inhibits the activity of FLT3 and prevents FLT3-mediated
downstream signaling. This inhibits the proliferation of FLT3-expressing cancer cells.
FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most
B-lineage neoplasms and in acute myeloid leukemias.;
Molecule name : BMF-500; BMF 500;
Origin ID : C201247;
- concept_is_in_subset
- has_target